George T. Grossberg, MD
Samuel W. Fordyce Professor
Director, Geriatric Psychiatry
Saint Louis University School of Medicine
St. Louis, Missouri
Richard D. Berchou, PharmD
Assistant Professor, Department of Psychiatry & Behavioral Neurosciences
Wayne State University College of Medicine
CREDIT FOR THIS PROGRAM IS AVAILABLE FOR PHARMACISTS ONLY.
The elderly population (>65 years) is growing exponentially and will continue to do so for another 30 or 40 years as the baby-boom generation begins to retire and require long-term care. Psychotic symptoms and behavioral disturbances among the elderly (e.g., paranoia, delusions, hallucinations, agitation, wandering, screaming, hiding objects), are highly prevalent. These disturbances are caused by a number of neuropsychiatric and biological changes, posing a challenge for physicians, pharmacists, and other care providers.
However, healthcare professionals require specialized knowledge of dosage, titration, and medication switching as the elderly often respond differently to medications from younger patients. Often, they are more sensitive to the effects of medications and more care is required in selecting and using pharmaceutical agents. In addition, the elderly frequently have comorbidities requiring additional medications and thereby making medication management even more complicated. This nationally renowned faculty in geriatric psychiatry and psychopharmacology provide insight into these complex issues, imparting real-world, practical information on dosing and titration strategies as well as monitoring potential side effects. Program Developer/Facilitator
. Target Audience
Pharmacists involved in caring for geriatric patients.
Upon completion of this audioconference, the participant should be able to:
Discuss the epidemiology and differential diagnoses of late-life psychoses and behavioral disturbances.
Explain the efficacy and side effects of conventional and atypical antipsychotics and their impact on elderly populations.
Elucidate the importance of developing an optimization strategy and rationale for drug switching, dosing, and monitoring in the elderly patient.
Identify emerging therapeutic approaches, agents, and delivery methods that may prove useful for future treatment of late-life behavioral disturbances.
Dr. Grossberg has received research grants/support from Abbott Laboratories, Bristol-Myers Squibb Company, Eli Lilly and Company, Forest Pharmaceuticals, Janssen Pharmaceutica, Novartis Pharmaceuticals Corporation, Organon, and Wyeth Pharmaceuticals. He has also received consulting fees from Abbott Laboratories, Eli Lilly and Company, Janssen Pharmaceutica, Novartis Pharmaceuticals Corporation, and Organon. He intends to discuss unapproved/investigative uses of a commercial product.
Dr. Berchou has served on the speakers’ bureau of AstraZeneca, Eli Lilly and Company, Janssen Pharmaceutica, and Novartis Pharmaceuticals Corporation. He intends to discuss unapproved/investigative uses of a commercial product.
Atypical antipsychotic drugs mentioned within this presentation are FDA approved for schizophrenia, only. None are indicated for dementia, Alzheimer’s disease, or psychoses.
Healthcare practitioners who participated in the audioconference or CD-ROM versions of this program are not eligible to receive continuing education credit through the online version.
This program (ACPE# 203-000-02-440-H01) was developed by the American Society of Consultant Pharmacists (ASCP) and is approved for 1.0 Contact Hour (0.1 CEU). ASCP is approved by the American Council on Pharmaceutical Education (ACPE) as a provider of continuing pharmaceutical education. Credit will be awarded upon submission of a completed program evaluation and a post-test with a passing grade of 70% or better.
Commercial Support Statements
Supported by an unrestricted educational grant from AstraZeneca.
Click on the "Start program" icon.
The next screen will permit you to check for or download RealAudio's RealPlayer required to run this program. You will also find buttons which will permit you to start the program presentation, access other program elements, and take the post-test.
Clicking on "start the program" on this screen will begin the program presentation which will take approximately 1 hour to complete.
You must be registered with cmecorner.com in order to complete the post-test. When you click on the post-test button you will be brought to a screen which will confirm your registration status and provide an opportunity to register if you haven't done so previously.
Instructions for completing and submitting the post-test are provided on the post-test screen. A minimum score of 70% on the post-test is required for a CE certificate.
The information contained in this program does not necessarily reflect the opinions or recommendations of the Dannemiller Memorial Educational Foundation, the American Society of Consultant Pharmacists, AKH Consultant, AstraZeneca, or Medical Communications Media, Inc. Diagnostic procedures or treatments discussed in the program should not be utilized by clinicians without evaluation of patients’ conditions and possible contraindications or risks, and without a review of applicable manufacturer’s product information and comparison with recommendations of other authorities.